What are liver fibrosis biomarkers

Automated blood test for liver fibrosis

January 31, 2012

Siemens offers the first rapid, automated biomarker test for diagnosing and assessing liver fibrosis. The ELF test (Enhanced Liver Fibrosis Test) takes around an hour. All he needs is a blood sample.

The new test was developed by Siemens Healthcare together with University College London and can be used as a routine test on the Siemens ADVIA Centaur immunoassay systems.

With the automated ADVIA Centaur ELF test, both the severity and the risk of further progression of liver fibrosis can now be detected quickly and gently. He investigates three direct blood serum biomarkers: hyaluronic acid (HA), procollagen III N-terminal propeptide (PIIINP) and the tissue inhibitor of metal proteinase 1 (TIMP-1). These direct biomarkers are molecules that are involved in the development of fibrosis. In the test, special reagents react with the biomarkers and generate light in the process. The more intense this chemiluminescence, the more biomarkers there are.

The results of the three biomarkers are converted into the ELF score using a special algorithm, which indicates the degree of fibrosis. The combination of the three biomarkers increases the accuracy of the test. As an international clinical study showed, the ELF test can precisely differentiate between minor, moderate and severe fibroses.

Press release Siemens, January 26, 2012
http://www.siemens.com/innovation/de/index.php

Messages

  • Fight hepatitis C together

    April 29, 2021: PLUS initiative

  • Hepatitis C.

    April 28, 2021: STI as a predictor of reinfection

  • COVID-19 and Public Health

    April 28, 2021: How did the public health service react to Corona in Germany?

  • Scholarship German Liver Foundation

    April 27, 2021: Application for an exemption scholarship for 2022 Hepatology is now possible.

  • Corona vaccination

    April 22, 2021: J & J's vector vaccine also effective against variants

  • HIV funding program

    April 20, 2021: You can apply for the Gilead HIV funding program until June 15, 2021.

  • Health Department Day

    March 19, 2021: The motto for the occasion "Crisis Response"

  • Corona vaccination

    March 14, 2021: EU approval for Janssen's single-use vaccine

  • Hepatitis D

    February 22, 2021: Non-quantifiable additional benefit for Hepcludex®

  • Hepatitis E.

    February 17, 2021: Viruses survive in the ejaculate of chronically infected patients

  • Hepatitis C.

    February 11, 2021: Need for clarification and action

  • Addendum DGVS guidelines HCV

    December 10, 2020: DGVS guideline recommends immediate start of therapy for chronic HCV infection.

  • Check-up 35

    November 22, 2020: Screening for hepatitis B and C is a new part of the health check-up

  • Hepatitis C.

    November 22, 2020: Addendum to the S3 guideline published

  • Flu shot

    November 15, 2020: Fluzone® High Dose Quadrivalent vaccine for people over 65 on the market

  • Test, advise, treat!

    October 20, 2020: Those interested can find out the most important things about hepatitis C in a new educational video

  • Hepatitis C.

    September 28, 2020: EASL guideline on rare genotypes

  • COVID-19

    September 25, 2020: ENSEMBLE vaccine study started

  • Hepatitis C.

    September 21, 2020: New EASL guideline recommends therapy for everyone.

  • PrEP

    September 21, 2020: HIV infection under PrEP

Older messages

This website provides information on all aspects of liver disease. The focus is on the viral hepatitis hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E, fatty liver and liver cancer. The clinical picture, diagnosis and therapy are treated. Much has changed in the treatment of hepatitis B and hepatitis C in particular. Here you will find an overview of the drugs available for hepatitis B and C, study data, specialist information and current prices. The current information from medicine and industry is aimed at those affected and doctors.